Pasithea Therapeutics Begins Promising Clinical Trial for PAS-004

Pasithea Therapeutics shares are trading higher after the company announced the initiation of a Phase 1/1b clinical trial for PAS-004 in adult NF1 patients, marking a significant milestone in its development.